In prediabetes (PD), circulating inflammatory biomarkers are associated with increased CVD1 risk. Exercise (Ex) has a positive effect on cardiovascular fitness and metabolic outcomes in PD but Ex effects on inflammation markers in PD are not fully known and were investigated in this study. Adults with PD (n=34) and normal fasting glucose (NG) (n=34) were randomised into one of four groups: NG control (NGC, n=16), NG Ex (NGE, n=18), PD control (PC, n=16) and PD Ex (PE, n=18). NGE/PE completed 12 weeks of supervised HIIT and progressive resistance training (PRT) 2 times/week, and NGC/PC unsupervised stretching 3 times/week. Baseline, age and weight were similar in PD and NG. Compared with NG, FPG and HbA1c were higher and VO2peak was significantly lower in PD (29±7 vs. 33±8 mL/kg/min, p=0.03). Comparing NG and PD at baseline, serum IL-1β was higher in NG (11.4±9.0 vs. 7.9±2.8 pg/mL, p=0.04), IL-12p70 and IL-22 were higher in PD (respectively, 5.7±3.6 vs. 4.4±2.2 pg/mL; 164.6±90.3 vs. 122.2±83.2 pg/mL, both p<0.05) and IL-1α, IL-6, IL-8, IL-15, M-CSF and TNFα were similar. At follow-up, HbA1c was reduced by -0.07±0.11% in NGE and -0.09±0.17% in PC (both p<0.05) and not changed in PE or NGC. PE had an increase in VO2peak (5.5±7.5mL/kg/min, p=0.01). Inflammatory biomarkers were unchanged in PE but NGE had reduced IL-12p70 (4.3±1.9 to 3.5±0.8 pg/mL, p=0.05) and M-CSF (124.5±58.2 to 93.8±36.2 pg/mL, p=0.02). Analysis of Ex with >80% adherence revealed that IL-1α, IL-1β, IL-8 and IL-15 were reduced in NGE, however no change was seen in PE despite a reduction in HbA1c of -0.14±0.17% (p=0.02). PD is associated with reduced cardiorespiratory fitness and increased IL-12p70 and IL-22. Ex reduced IL-12p70 and M-CSF in those with NG but not PD, even after stratifying by adherence and despite improvements in clinical markers. This study indicates low volume HIIT with PRT may not be adequate to reduce serum inflammatory biomarkers in prediabetes.


C. J. Baker: None. D. Min: None. J. Gerofi: None. X. Wang: None. S. L. Hocking: Advisory Panel; Self; Eli Lilly and Company, Inova, Novo Nordisk, Pfizer Inc. S. Colagiuri: None. N. A. Johnson: None. S. M. Twigg: Advisory Panel; Self; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi-Aventis, Consultant; Self; Aktivo Labs, Sanofi-Aventis, Research Support; Self; Abbott Diabetes, Speaker’s Bureau; Self; Abbott Diabetes, AstraZeneca.


National Health and Medical Research Council (APP1113612)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at